← Back to searchRecruitingRecruiting
Association Between LRG and Histologic Remission in Ulcerative Colitis
NCT06372613 · Showa Inan General Hospital
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
What is the Level of Serum Leucine-rich α 2-glycoprotein (LRG) Which Predicts Histologic Remission in Patients With Ulcerative Colitis?
About this study
Aim: Serum leucine-rich α 2-glycoprotein (LRG) may be a noninvasive biomarker for monitoring disease activity in patients with ulcerative colitis (UC). We attempt to clarify the LRG level which predicts histologic remission in UC patients in this study.
Methods: Patients with UC were consecutively enrolled with the measurement of serum LRG. Colonoscopy with histology is performed when histologic remission is predicted, irrespective of symptoms or serum LRG values. Serum LRG levels are analyzed by an enzyme-linked immunosorbent assay. For the evaluation of UC activity, clinical remission was defined as score 1 or 0 using the partial Mayo score and endoscopic remission was defined as score 0 using the Mayo endoscopic subscore. And histologic remission is defined as \< grade 2 using Geboes score. We analyze the area under receiver operating characteristic (ROC) curves to evaluate the diagnostic ability of LRG for predicting histologic remission of UC.
Eligibility criteria
Inclusion Criteria:
* active UC patients
Exclusion Criteria:
* None
Study design
Enrollment target: 100 participants
Age groups: adult, older_adult
Timeline
Starts: 2024-02-25
Estimated completion: 2025-12-31
Last updated: 2025-08-22
Primary outcomes
- • Histologic remission of UC (1 week)
Sponsor
Showa Inan General Hospital · other
Contacts & investigators
ContactAkia Horiuchi · contact · horiuchi.akira@sihp.jp · 09021684311
All locations (1)
Showa Inan General HospitalRecruiting
Komagane, Japan